Silverback Net Receivables from 2010 to 2025

SPRY Stock   12.57  0.39  3.20%   
Silverback Therapeutics Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables will likely drop to about 602 K in 2025. During the period from 2010 to 2025, Silverback Therapeutics Net Receivables regression line of annual values had r-squared of  0.25 and arithmetic mean of  471,577. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
914.2 K
Current Value
602 K
Quarterly Volatility
246.6 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Silverback Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Silverback Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.4 K, Other Operating Expenses of 81.6 M or Research Development of 20.8 M, as well as many indicators such as Price To Sales Ratio of 16.4 K, Dividend Yield of 0.0 or PTB Ratio of 2.14. Silverback financial statements analysis is a perfect complement when working with Silverback Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Silverback Therapeutics Correlation against competitors.
For more information on how to buy Silverback Stock please use our How to Invest in Silverback Therapeutics guide.

Latest Silverback Therapeutics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Silverback Therapeutics over the last few years. It is Silverback Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Silverback Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Silverback Net Receivables Regression Statistics

Arithmetic Mean471,577
Geometric Mean319,547
Coefficient Of Variation52.29
Mean Deviation179,240
Median384,000
Standard Deviation246,603
Sample Variance60.8B
Range1M
R-Value0.50
Mean Square Error48.8B
R-Squared0.25
Significance0.05
Slope25,923
Total Sum of Squares912.2B

Silverback Net Receivables History

2025602 K
2024914.2 K
2023795 K
2022M
2021 1000.0

About Silverback Therapeutics Financial Statements

Silverback Therapeutics investors use historical fundamental indicators, such as Silverback Therapeutics' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Silverback Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables914.2 K602 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Silverback Stock Analysis

When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.